Control Bionics (ASX:CBL) Buyback Yield %: -21.85 (As of Jul. 03, 2026)


What is Control Bionics Buyback Yield %?

Control Bionics ASX:CBL -0.67% Buyback Yield % is -21.85 as of Jul. 03, 2026. The stock has 4 warning signs investors should review. Among 347 Medical Devices & Instruments companies, Control Bionics ranks worse than 81.56% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Control Bionics's current buyback yield was -21.85%.

Control Bionics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Control Bionics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics Buyback Yield % Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial -25.79 -0.07 -9.52 -48.06 -58.98

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42.02 -48.06 -35.92 -58.98 -28.62

ASX:CBL vs ABT, SYK, MDT: Buyback Yield % Comparison

For the Medical Devices subindustry, Control Bionics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Control Bionics Buyback Yield % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Control Bionics's Buyback Yield % falls into.


Control Bionics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Control Bionics's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.193 + 5.406) / 8.838285945
=-58.98%

Control Bionics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.084 + 7.277) / 25.129682
=-28.62%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -21.85 mean?
Control Bionics (ASX:CBL) has a Buyback Yield % of -21.85 as of Jul. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Control Bionics and its competitors. According to the industry distribution chart, Control Bionics ranks #283 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 81.6%.
Is Control Bionics' Buyback Yield % too high?
Control Bionics' current Buyback Yield % is -21.85. Based on the distribution chart, Control Bionics ranks #283 out of 347 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Control Bionics' Buyback Yield % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #283 out of 347 companies for Buyback Yield %. This places Control Bionics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Control Bionics and its competitors. Control Bionics's current Buyback Yield % is -21.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 146.7% above its estimated fair value. The current Buyback Yield % is -21.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Buyback Yield % is -21.85 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.